InvestorsHub Logo
Followers 826
Posts 119467
Boards Moderated 15
Alias Born 09/05/2002

Re: None

Monday, 06/04/2018 5:48:42 PM

Monday, June 04, 2018 5:48:42 PM

Post# of 294
FDA approves MYL’s Fulphila—a Neulasta FoB:

https://www.prnewswire.com/news-releases/us-fda-approves-mylan-and-biocons-fulphila-pegfilgrastim-jmdb-the-first-biosimilar-to-neulasta-300659410.html

Neulasta is a tricky drug for FoBs to match due to its unusual pharmacokinetics. This is the first successful attempt in the US after a couple of failures (NVS, CHRS).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VTRS News